Skin Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 53 Patients

G-alone G-cyclo P-value No. of patients 112 (81%) 26 (19%) Median age (years; range) 61 (36-72) 55 (35-65) Male/female 65(58%)/47(42%) 17(65%)/9(35%) P1⁄40.47 Prior radiotherapy exposure 17 (15%) 5 (19%) P1⁄40.61 Median no. of bortezomib doses 16 (11-24) 16 (15-20) Median cumulative bortezomib dose (mg/m) 20.8 (14.3 e 31.2) 20.8 (16.0-22.1) Cyclophosphamide mobilisation dose 1.5 g/m NA 7 (24%) 2 g/m NA 19 (76%) G-CSF dose for mobilisation 5mg/kg daily 0 7 (27%) 10mg/kg daily 96 (86%) 18 (69%) 10mg/kg twice daily 16 (14%) 0 NA 0 1 (4%) PB CD34+ day of planned collection (10/L; median; range) 52 (8-326) 69 (0-227) P1⁄40.87 u003e100 26 (23%) 8 (31%) u003e50-100 31 (28%) 7 (27%) 20-50 39 (35%) 8 (31%) 4-6 49 (44%) 11 (44%) u003e6 44 (40%) 12 (48%) Median CD34+ yield in radiotherapy patients (10/kg; range) 5.8 (2.2-17.3) 4.5 (3.8-6.9) Outcomes of collection Success without intervention 38 (34%) 13 (50%) P1⁄40.49 Success with extra days of G-CSF 62 (55%) 11 (42%) Success with plerixafor rescue 7 (6%) 1 (4%) Failed first collection; no other attempts 1 (1%) 0 Failed first collection with subsequent successful collection 3 (3%) 1 (4%) Target yield not reached but deemed sufficient 1 (1%) 0